Axoltis Pharma Overview

  • Founded
  • 2003
  • Status
  • Private
  • Employees
  • 8
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $1.24M
Latest Deal Amount
  • Investors
  • 6

Axoltis Pharma General Information


Developer of first-in-class innovative drugs designed to treat patients suffering from traumatic or severe neurological disorders. The company's drugs support neural repair in order to treat traumatic or severe degenerative disorders of the central nervous system faced with high unmet medical needs, enabling patients with the extension of its potential to the treatment of neurodegenerative diseases and o improve the patients' functional recovery and quality of life.

Contact Information

Formerly Known As
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 15 - 17, Rue du Pré de la Reine
  • 63100 Clermont-Ferrand
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Axoltis Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 19-Dec-2014 $1.24M 00.000 Completed Profitable
1. Grant 01-Oct-2012 00000 Completed Generating Revenue
To view Axoltis Pharma’s complete valuation and funding history, request access »

Axoltis Pharma Executive Team (9)

Name Title Board Seat Contact Info
Yann Godfrin Ph.D Chief Executive Officer
Luca Bolliger Ph.D Chief Business Officer & Board Member
Pierre Goineau Chairman
Valérie Bourdès MD Chief Medical Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Axoltis Pharma Board Members (7)

Name Representing Role Since
Foucauld Pouet Axoltis Pharma Board Member 000 0000
François Miceli Sofimac Investment Managers Supervisory Board Member 000 0000
Gilles Avenard Axoltis Pharma Board Member 000 0000
Isabelle Baillenx Self Board Observer 000 0000
Luca Bolliger Ph.D Axoltis Pharma Chief Business Officer & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Axoltis Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axoltis Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angelor Angel Group Minority 000 0000 000000 0
Auvergne Business Angels Angel Group Minority 000 0000 000000 0
FaDiese Venture Capital Minority 000 0000 000000 0
JEREMIE Auvergne Venture Capital Minority 000 0000 000000 0
Sofimac Investment Managers Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »